Neovacs S.A SMA 50
Quel est le SMA 50 de Neovacs S.A?
Le SMA 50 de Neovacs S.A. est €0 +100.00%
Quelle est la définition de SMA 50?
SMA 50 est un cours moyen des 50 derniers jours calculé comme une moyenne non pondérée des 50 derniers cours de clôture.
Simple moving average of 50 days for a stock is an unweighted moving average over the past 50 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
SMA 50 des entreprises dans Health Care secteur sur EURONEXT par rapport à Neovacs S.A
Que fait Neovacs S.A?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Entreprises avec sma 50 similaire à Neovacs S.A
- Neovacs S.A a SMA 50 de €0 +100.00%
- EVmo Inc a SMA 50 de $0 +99.75%
- Blue Capital Reinsurance Ltd a SMA 50 de $0 -Inf%
- Kaleido Biosciences Inc a SMA 50 de $0 +59.40%
- Yangtze River Port and Logistics Ltd a SMA 50 de $0 +28.25%
- iFresh Inc a SMA 50 de $0 +0.00%
- Aridis Pharmaceuticals Inc a SMA 50 de $0 +83.25%